Breast Cancer

Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.

Antoinette Tan, MD, MHS, discusses the implications of the DESTINY-Breast06 trial of T-DXd vs chemotherapy in HER2-low or -ultralow breast cancer.

Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.

Treatment with HER3-DXd led to intracranial responses with a tolerable safety profile in patients with metastatic breast cancer and brain metastases.

Real-world analysis showed ctDNA positivity was associated with higher recurrence risk and reduced overall survival in early breast cancer.

Panelists discuss how to contextualize inavolisib within the broader landscape of PIK3CA inhibitors, noting its improved tolerability compared with alpelisib while emphasizing the need for individualized treatment selection based on disease burden and the emerging challenge of managing comutations like ESR1.

Panelists discuss how the INAVO120 trial’s secondary end point showing delayed time to chemotherapy from 12 to 36 months with the triplet combination provides compelling quality-of-life benefits for patients while acknowledging the challenges of determining optimal treatment sequencing after progression on this regimen.

Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Henry Kuerer, MD, PhD, discusses considerations for the selective omission of surgery in HER2-positive breast cancer or triple-negative breast cancer.

Adjuvant ribociclib plus endocrine therapy has gained Canadian approval for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.

The FDA granted fast track designation to RAD101 for imaging of cerebral metastases from various solid tumors, including leptomeningeal metastases.

Liquid biopsy approaches aid in precision therapy selection for patients with breast cancer in a noninvasive manner.

Sarah Sammons, MD, discusses data from the phase 1 ReDiscover trial of RLY-2608 plus fulvestrant in HR-positive, HER2-negative breast cancer.

Elacestrant-based combinations were safe and displayed preliminary efficacy in ER-positive/HER2-negative advanced breast cancer.

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

The FDA received an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation.

The European Medicines Agency's CHMP has recommended the use of denosumab biosimilars referencing Prolia and Xgeva in all reference product indications.

Patients with metastatic breast cancer with higher HER2 amplicon mRNA signatures prior to T-DXd therapy had better outcomes vs those with lower signatures.

Sacituzumab govitecan in combination with pembrolizumab led to pathologic complete responses in early-stage triple-negative breast cancer.

Ribociclib plus a nonsteroidal aromatase inhibitor improved iDFS, DDFS, RFS, and DRFS in HR+/HER2– early breast cancer.